Thread by @karanpdesai

Join now as Dr. Mann gives a keynote on HF in 2022 in the era of SGLT2i #THT2022

“Predicting the future isn’t what it used to be” - Yogi Berra

In era where definitions of HF are becoming blurred, how do we define the role of therapies? A talk pertinent for all cardiologists

Followed by @NirUrielMD talking about the future of HF and pointing out this fantastic paper from @HRRosenblum on a device-based approach to ADHF w/ the DRI2️⃣P2️⃣S approach

Read paper here: ahajournals.org/doi/full/10.11…

@BrenerMickey @ersied727 @zilgiovineMD @tremartyn @AHajduczok

What a whirlwind tour by @GreggWStone on how the sausage gets made with HF device clinical trials

Look at all the factors: critical background on understanding how the evidence forms for the science we apply at the bedside

@mvaduganathan @FudimMarat @vbluml @SJGreene_md

Dr. @amorrismd giving a powerful talk on the under representation of diverse populations in HF trials, as well amongst investigators

Would encourage also to listen to this @CardioNerds episode with @shirleneobuobi on AHF therapy disparities: cardionerds.com/105-narratives…

Dr. @LindenfeldJoann breaking down how patient behavior and HF events changed during COVID-19 pandemic with data from Guide-HF #THT2022

What factors were at play leading to behavior modification: adherence? Diet?

Look at PAP data pre and during the pandemic